Our DNA

Driving for Success

At Life Technologies, we embrace our diversity of thought and celebrate the values that unite us. We build our stewardship of the global life science community on this bedrock of shared beliefs.

WE CREATE TRANSFORMATIVE SCIENCE. We believe in the power of science and appreciate its rigorous discipline. Our vision that science has the power to change lives drives our passion for innovation, leading to transformative offerings that support scientific endeavors and their critical impact on society.

WE DELIVER TANGIBLE QUALITY. From our products that consistently perform, to our relationships with customers, our commitment to excellence is unwavering. For our customers, our shareholders and all of society, we always deliver.

WE MAINTAIN POSITIVE MOMENTUM. Our stakes are high. Our consequent sense of urgency creates uncommon momentum in our innovation process, fueling a race to discovery without compromising quality. Our employees understand the importance of their work, and have the courage to move fast and take risks, to propel science forward.

WE ARE ALWAYS CONNECTED. Our employees and their knowledge are called on first when our industry meets a tough challenge. We encourage this by building advisory relationships based on trust and open dialogue with customers and employees at every level. We connect people to science by making access to thought leadership, collaboration and our product portfolio as easy as possible.

WE LIVE AS GLOBAL CITIZENS. Our global reach gives us a vantage point that engenders a sense of responsibility to serve both science and society. This builds a devoted corporate culture, evidenced by our dedication to the future of science, our deep respect for our environment and our unyielding commitment to doing the right thing.


Search for jobs now >

News

  • TGen Study

    LifeTechnologies Corporation announced that it is collaborating with the Translational Genomics Research Institute (TGen) and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies. The goal of this first-of-its-kind research collaboration is to demonstrate whether genomic sequencing of cancer tissue can provide clues for treatment strategies for these individuals.

    Read All Close
  • SMS Technology

    Life Technologies Corporation announced early stage results from its single molecule sequencing (SMS) technology. The technology promises to combine virtually unlimited continuous long read lengths with unmatched accuracy to deliver targeted genomic sequence data in a matter of hours, paving the way for sequencing to become a commonplace tool in research laboratories and clinical settings worldwide.

    Read All Close
  • SOLiD PI ANNOUNCED

    Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD(TM) PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.

    Read All Close

Life (Common Stock)